Citius Pharmaceuticals CTXR
NASDAQ CTXR
$0.56 +0.00 (+0.67%)
As of: Sep 30, 2026 · 12:07 PM EDT

Citius Pharmaceuticals (CTXR) EBIT Margin (2025 - 2026)

Updated

Citius Pharmaceuticals (CTXR) reported EBIT Margin of -785.39% for fiscal Q3 2026 (quarter ended Jun 30, 2026), up 1145.56 percentage points from the prior quarter.

Analysis

Citius Pharmaceuticals (CTXR) EBIT Margin (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Citius Pharmaceuticals' EBIT Margin came in at -863.92%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 28.21%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 37.86%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -3.52%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 32.97%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 20.57%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 34.95%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 37.40%
10 Citius Pharmaceuticals 15.10 Mn 24.39 Mn 1.00 Mn -785.39%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -785.39%
Mar 31, 2026 -1,930.96%
Dec 31, 2025 -228.68%
API Access

Citius Pharmaceuticals EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=CTXR&period=max&api_key=YOUR_API_KEY